

Supplemental Figures for:
Patient-reported outcomes predict progression-free survival of patients with advanced breast cancer treated with abemaciclib
Sarah Badaoui et al.




Figure S1: Kaplan Meier comparisons of PFS by pre-treatment ECOG-PS for the randomised arms of MONARCH 2 and MONARCH 3 (abemaciclib versus comparator).